1. Home
  2. SELF vs ALXO Comparison

SELF vs ALXO Comparison

Compare SELF & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Self Storage Inc.

SELF

Global Self Storage Inc.

HOLD

Current Price

$5.19

Market Cap

57.3M

Sector

Real Estate

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.20

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SELF
ALXO
Founded
1983
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.3M
68.3M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
SELF
ALXO
Price
$5.19
$2.20
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.42
AVG Volume (30 Days)
27.8K
1.0M
Earning Date
01-01-0001
06-01-2026
Dividend Yield
5.57%
N/A
EPS Growth
N/A
31.02
EPS
0.15
N/A
Revenue
$12,530,280.00
N/A
Revenue This Year
$1.59
N/A
Revenue Next Year
$1.62
N/A
P/E Ratio
$34.40
N/A
Revenue Growth
2.79
N/A
52 Week Low
$4.73
$0.41
52 Week High
$5.83
$2.66

Technical Indicators

Market Signals
Indicator
SELF
ALXO
Relative Strength Index (RSI) 58.94 54.46
Support Level $5.12 $1.41
Resistance Level $5.19 $2.27
Average True Range (ATR) 0.08 0.25
MACD 0.02 -0.06
Stochastic Oscillator 63.67 32.31

Price Performance

Historical Comparison
SELF
ALXO

About SELF Global Self Storage Inc.

Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: